Research programme: ion channel-targeting therapeutics - Boehringer Ingelheim/Broad Institute
Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Broad Institute
- Developer Boehringer Ingelheim; Broad Institute
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mental disorders